scholarly journals DP1 prostanoid receptor activation increases the severity of an acute lower respiratory viral infection in mice via TNF-α-induced immunopathology

Author(s):  
Md Ashik Ullah ◽  
Sonja Rittchen ◽  
Jia Li ◽  
Sumaira Z. Hasnain ◽  
Simon Phipps
2021 ◽  
Vol 41 (3) ◽  
Author(s):  
Fangyan Wang ◽  
Binhui Pan ◽  
Sheng Xu ◽  
Zhihua Xu ◽  
Tiaotiao Zhang ◽  
...  

Abstract Experimental experience suggests that microbial agents including probiotics and prebiotics (representative microbial agents) play a critical role in defending against respiratory virus infection. We aim to systematically examine these agents’ effect on respiratory viral infection and encourage research into clinical applications. An electronic literature search was conducted from published data with a combination of a microbial agents search component containing synonyms for microbial agents-related terms and a customized search component for respiratory virus infection. Hazard ratio (HR), risk ratio (RR) and standard deviation (SD) were employed as effect estimates. In 45 preclinical studies, the mortality rates decreased in the respiratory viral infection models that included prebiotics or prebiotics as interventions (HR: 0.70; 95% confidence interval (CI): 0.56–0.87; P=0.002). There was a significant decrease in viral load due to improved gut microbiota (SD: −1.22; 95% CI: −1.50 to −0.94; P<0.001). Concentrations of interferon (IFN)-α (SD: 1.05; 95% CI: 0.33–1.77; P=0.004), IFN-γ (SD: 0.83; 95% CI: 0.01–1.65; P=0.05) and interleukin (IL)-12 (SD: 2.42; 95% CI: 0.32–4.52; P=0.02), IL-1β (SD: 0.01; 95% CI: −0.37 to 0.40; P=0.94) increased, whereas those of TNF-α (SD: −0.58; 95% CI: −1.59 to 0.43; P=0.26) and IL-6 (SD: −0.59; 95% CI: −1.24 to 0.07; P=0.08) decreased. Six clinical studies had lower symptom scores (SD: −0.09; 95% CI: −0.44 to 0.26; P=0.61) and less incidence of infection (RR: 0.80; 95% CI: 0.64–1.01; P=0.06). Our research indicates that probiotics and prebiotics pose a defensive possibility on respiratory viral infection and may encourage the clinical application.


2019 ◽  
Vol 24 (2) ◽  
pp. 161-166 ◽  
Author(s):  
О. A. Uspenskaya ◽  
S. A. Spiridonova

Relevance. One of the causes of chronic disease is herpetic infection, lifelong persistence in the human body and activates the macrophage protection system, which leads to disruption of iron utilization by the cells of the hematopoietic system and the development of anemia of chronic disease. To prove the influence of herpesvirus infection on the occurrence of anemia of chronic disease.Materials and methods. The study involved 75 people suffering from herpes-viral infection. 3 groups were allocated: the frst group (25 people) received acyclovir 1 tablet (200 mg) 5 times a day, 5 days; The 2-nd group (25 people) used famvir for 1 tablet (250 mg) 2 times a day, 5 days; The third group (25 people) – famvir 1 tablet (250 mg) 2 times a day, 5 days and kagocel 2 tablets (12 mg) 3 times a day, 5 days.Result. All subjects examined at the time of treatment showed an increase in the content of IL 1β mRNK and TNF-α and a decrease in mRNK of IL 8 and IL 10; on day 14 of the study, a decrease in IL 1β mRNK and TNF-α mRNK and an increase in IL 10 mRNK. In the study of erythrocyte indices – the average volume of erythrocytes and the average hemoglobin content in erythrocyte and the parameters of iron-serum iron metabolism and the total iron binding capacity of the serum, slight deviations from the norm were obtained.Conclusions. Thus, we concluded that the cause of anemia, in addition to the lack of iron, can be chronic herpesvirus infection, and thus timely treatment of a viral infection excludes the use of ferrotherapy.


2011 ◽  
Vol 30 (4) ◽  
pp. S122
Author(s):  
D.C. Chambers ◽  
A. Burke ◽  
T.W.V. Daniels ◽  
S.T. Yerkovich ◽  
P.M.A. Hopkins

Sign in / Sign up

Export Citation Format

Share Document